1	Diagnostic performance of LumiraDx SARS-CoV-2 rapid antigen test compared to PCR
2	for diagnosis of COVID-19 in Liberia
3	
4	Moses Badio <sup>a,b</sup> , Christina Lindan <sup>b</sup> , Kumblytee Johnson <sup>a</sup> , Cavan Reilly <sup>c</sup> , Julie Blie <sup>a</sup> , Katy Shaw-
5	Saliba <sup>d</sup> , Tamba Fayiah <sup>a</sup> , John McCullough <sup>e</sup> , J. Tanu Duworko <sup>a</sup> , Elizabeth Higgs <sup>d</sup> , Jeffrey
6	Martin <sup>b</sup> , Lisa Hensley <sup>d</sup>
7	
8	<sup>a</sup> Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL),
9	Monrovia, Liberia; <sup>b</sup> Department of Epidemiology and Biostatistics, University of California,
10	San Francisco, San Francisco, California, USA; <sup>c</sup> Division of Biostatistics, University of
11	Minnesota, Minneapolis, Minnesota, USA; <sup>d</sup> National Institute of Allergy and Infectious
12	Diseases, U.S. National Institutes of Health, Bethesda, Maryland, USA; and Advanced
13	BioMedical Laboratories, LLC, Cinnaminson, New Jersey, USA
14	
15	Corresponding author: Moses Badio, Department of Epidemiology & Biostatistics, UCSF, 550
16	16 <sup>th</sup> Street, San Francisco, California, 94158
17	Email address: mbadio@prevailcr.org, moses.badio@ucsf.edu
18	
19	Keywords: Point of Care, Near Patient Testing, Virology, PCR, Nucleic Acid Amplification
20	Test, Patient Management, Antimicrobial Stewardship
21	
22	Funding: This research was supported by the U.S. National Institutes of Health/National
23	Institute of Allergy and Infectious Disease (NIH/NIAID), Partnership for Research on Ebola

- 24 Virus in Liberia (PREVAIL); the Fogarty International Center/NIAID (U2R TW011281); and
- the U.S. National Institute of Mental Health/NIH (R25 MH123256).

## 26 Abstract

27	Background: Diagnosis of SARS-CoV-2 infection in Liberia has primarily relied on polymerase
28	chain reaction (PCR)-based testing at the country's National Reference Laboratory. This
29	centralized approach caused reporting delays, prompting evaluation of point-of-care antigen-
30	based tests. We assessed the test performance of the LumiraDx <sup>TM</sup> SARS-CoV-2 Ag test
31	(LumiraDx <sup>TM</sup> , London, UK) in this setting.
32	Methods: We tested ambulatory individuals screened for enrollment into an observational cohort
33	study of COVID-19 sequelae in Monrovia in 2021. We compared the results of LumiraDx
34	testing of anterior nasal swab specimens to the results of PCR BioFire® R2.1P (bioMérieux, Salt
35	Lake City, Utah) on eluent from nasopharyngeal swabs.
36	Results: We evaluated 348 individuals. Among the 274 persons with symptoms, 49.3% were
37	PCR-positive and 36.5% were antigen-positive. The sensitivity, specificity, negative predictive
38	value (NPV), and positive predictive value (PPV) of LumiraDx in this group were 72.6% (95%
39	CI: 64.3%-79.9%), 98.6% (95% CI: 94.9%-99.8%), 78.7% (CI: 71.9%-84.6%), and 98.0% (CI:
40	93.0%-99.8%), respectively. Among the 74 asymptomatic individuals, 12.2% were positive by
41	PCR, and 5.5% by antigen testing, resulting in a sensitivity, specificity, NPV, and PPV of
42	LumiraDx of 44.4% (95% CI: 13.7%-78.8%), 100% (95% CI: 94.5%-100%), 92.9% (CI: 84.1%-
43	97.6%), and 100% (CI: 39.8%-100%), respectively.
44	Conclusion: Although the specificity and PPV of LumiraDx for diagnosing SARS-CoV-2 were
45	high among persons with and without symptoms, the sensitivity was unacceptably low in both
46	groups, and much less than that reported by the manufacturer. Before new point-of-care
47	diagnostics are adopted, test performance needs to be assessed in the local setting.

## 49 Introduction

50 A global shortage of laboratory tests to detect SARS-CoV-2 infection occurred during the 51 beginning of the COVID-19 pandemic due to high demand and disruptions in supply chains; this 52 was particularly true in many parts of sub-Saharan Africa (SSA)[1-4]. In resource-limited 53 settings, identifying persons with COVID-19 was further complicated by the lack of alternative 54 and accurate rapid tests, causing reliance on reverse-transcriptate polymerase chain reaction 55 (PCR) to detect the presence of SARS-CoV-2 RNA. PCR technology has been the gold standard 56 for diagnosis, but requires specialized and costly equipment and reagents; processing can result 57 in lengthy delays in obtaining results[2], hindering recommendations for people to quarantine or 58 isolate, and preventing timely provision of available treatment, in turn impairing the ability to reduce ongoing transmission[3]. The limitations of laboratory-based PCR testing spurred the 59 60 development of point-of-care (POC) rapid antigen-based diagnostics, well as self-administered home-based testing[4]. 61

62 In Liberia, laboratory-confirmed diagnosis of SARS-CoV-2 infection relied exclusively on PCR testing at the National Reference Laboratory (NRL). Specimens from all 15 counties in 63 the country had to be transported to the NRL; the laboratory was difficult to access and could 64 65 only be reached using unpaved roads. This centralized approach caused reporting delays of at least two weeks due to low throughput of the PCR platform and the logistical difficulty of 66 transporting specimens. These constraints were acutely experienced during a surge of SARS-67 CoV-2 transmission from June to August 2021, primarily attributed to the delta-variant[5,6]. 68 During this period, a large number of people with respiratory symptoms presented to health 69 facilities, but diagnosis and management of COVID-19 were impaired due to the inability to 70

obtain test results quickly. Neither POC nor self-administered home-based rapid antigen tests
were available in Liberia at the time.

73 The PREVAIL COVID-19 Observational Study (PCOS), a research collaboration 74 between the U.S. National Institute of Allergy and Infectious Diseases/National Institute of Health (NIAID/NIH) and the Liberian Ministry of Health (MOH), was set up in August 2020 at 75 76 the JFK Hospital, the main referral hospital in the country. The goals of PCOS were to evaluate 77 the acute and long-term sequelae of SARS-CoV-2 infection by evaluating symptomatic and asymptomatic infected individuals over time, as well as a comparator group of uninfected 78 79 persons. Potential participants were screened for infection using the BioFire® R2.1P 80 (bioMérieux, Salt Lake City, Utah) at the PCOS research laboratory at the JFK hospital. The 81 Liberian MOH requested assistance from PCOS to evaluate the utility and accuracy of the 82 LumiraDx<sup>TM</sup> SARS-CoV-2 antigen test (LumiraDx, London, UK). This platform was being 83 considered by the MOH for use at clinical sites around the country to hasten diagnoses and reduce the burden on NRL, if it performed well in comparison to PCR. Assessment of the local 84 85 test performance of LumiraDx was considered important, in part because it was not known how 86 POC diagnostic tests would perform in the Liberian population, especially given early 87 indications of less severe clinical disease in many parts of SSA compared to populations in 88 Europe, South America, and the U.S[7-9].

89 Methods

## 90 Study design and summary

We evaluated the test performance of the LumiraDx antigen test compared to the results
of the BioFire PCR on eluent from nasal swabs obtained from symptomatic and asymptomatic

- 93 individuals being screened for enrollment into PCOS. Both tests had received U.S. FDA
- Emergency Use Authorization at the time of the study [8,9].

#### 95 Study population

96 Persons of any age who were ambulatory and seeking outpatient care at the JFK Hospital 97 for any reason and who had symptoms consistent with COVID-19 were referred by clinicians to 98 the PCOS testing site for study information, testing for SARS-CoV-2, and recruitment. Individuals from the community who voluntarily sought testing, regardless of symptoms, could 99 100 also be tested, and if interested, evaluated for enrollment. In this analysis, we present data from a 101 consecutive sample of persons who were screened from June to August 2021, regardless of 102 whether they subsequently enrolled in PCOS. All persons provided written informed consent for screening procedures, and a completed a separate signed consent if they decided to enroll in 103 104 PCOS. The study was reviewed and approved by the Liberian National Research Ethics Board. 105 Measurements and laboratory testing Participants completed a short interviewer-administered survey about socio-106 107 demographics and whether they had experienced any of 10 COVID-19-related symptoms during 108 the last two weeks; at the time, these symptoms were included on the MOH screening algorithem 109 for COVID-19.

Nasopharyngeal (NP) HydraFlock swabs for PCR testing and anterior nasal HydraFlock
swabs for antigen testing were collected by trained laboratory technicians. Each swab was
rotated for 10-15 seconds in both nares. NP swabs were immediately placed in 3 mL of viral
transport media, and eluent tested within 45 minutes using BioFire at the PCOS research
laboratory co-located at JFK Hospital, following manufacturer guidelines[11]. The BioFire

targets the viral spike (S) and membrane (M) proteins. Anterior nasal swabs were immediately
placed in pre-packaged extraction buffer and tested within 30 minutes using the LumiraDx
instrument according to the manufacturer's instructions[12]. This test uses a microfluidic
immunofluorescence-based assay for the qualitative detection of the SARS-CoV-2 nucleocapsid
protein. Laboratory technicians wore personal protective equipment (PPE) including gowns,
surgical caps, masks, and gloves during specimen collection, handling, and testing; gloves were
changed between the processing of each individual specimen.

## 122 Statistical analysis

123 The distribution of age, gender, and symptoms were computed using proportions. We determined the 'prevalence' or pre-test probability of infection in the whole sample, and among 124 persons with and withought symptoms, based on the proportion with a positive BioFire PCR test. 125 We calculated the sensitivity, specificity, positive predictive value (PPV), and negative 126 predictive value (NPV) of LumiraDx with 95% confidence intervals (CI) among the entire 127 128 sample, as well as stratified by whether persons had symptoms or not. Based on the sensitivity 129 and specificity of the antigen test in our sample, we estimated the PPV and NPV among persons with and without symptoms at varying levels of pre-test probability of SARS-CoV-2 infection. 130 131 Analyses were conducted using Stata version 17.0 (Stata Corporation, College Station, Texas, United States). 132

### 133 Results

Among the 348 individuals evaluated, 44.3% were female; the age range was 8 to 86 years, and 44.3% were 30 years of age or less (Table 1). More than three-fourths (78.7%)

136	reported at least one COVID-19-related symptom in the last two weeks. The most common
137	symptoms were weakness (50.9%), cough (42.2%), body pain (37.9%), and fever (37.1%).
138	Among all NP specimens tested by BioFire, 41.4% were positive for detection of SARS-
139	CoV-2 RNA; among all anterior nasal specimens tested using LumiraDX, 29.9% were positive
140	(Table 2). Among samples from the 274 persons with symptoms, 49.3% were PCR-positive, and
141	36.5% were antigen-positive. The sensitivity, specificity, NPV and PPV of LumiraDx in this
142	group were 72.6% (95% CI: 64.3% to 79.9%), 98.6% (95% CI: 94.9% to 99.8%), 78.7% (71.9%,
143	84.6%), and 98.0% (93.0%, 99.8%) respectively. Among samples from the 74 asymptomatic
144	individuals, 12.2% were positive by PCR and 5.4% were positive by antigen-testing. The
145	sensitivity, specificity, NPV, and PPV of LumiraDx in persons without symptoms were 44.4%
146	(95% CI: 13.7% to 78.8%), 100% (95% CI: 94.5% to 100%), 92.9% (84.1%, 97.6%), and
147	100.0% (39.8%, 100%) respectively.

Based on our calculated sensitivity and specificity, we estimated that among persons with symptoms, the PPV of LumiraDx would be >=90% when the true prevalence of infection is 150 15% or higher (Figure). In symptomatic persons, the NPV increases as the prior-probability of 151 infection, decreases, reaching >= 90% when the true prevalence is 30% or less. Among 152 asymptomatic persons, the NPV would be high, or >=90%, when the true prevalence of 153 infection is 16% or less. The PPV among asymptomatic individuals at varying levels of 154 prevalence could not be calculated, however, because the specificity was 100%.

#### 155 **Discussion**

We evaluated the test performance of the LumiraDx SARS-CoV-2 Ag test compared tothe BioFire PCR in Liberia and found that among persons both with and without symptoms, the

antigen test had a high specificity and PPV of 98% -100%. In contrast, the sensitivity was
unacceptably low: 73% in persons with symptoms, and 44% among asymptomatic people. This
means that in someone presenting with symptoms suggestive of COVID-19, a negative test
would need to be corroborated by a PCR or other nucleic acid amplification test (NAAT),
particularly at higher levels of community prevalence. Because of these findings, the Liberian
MOH decided not provide LumiraDx to local hospitals and clinics as an alternative decentralized
method of diagnosing infections.

The sensitivity of LumiraDx that we found in our Liberian sample was substantially 165 166 different from the 97.6% presented in the manufacturer's insert [13] and a publication based on 167 the same data [14]. It should be noted that the the product insert and the paper by Drain et al, do not specify the symptom status of those tested using anterior nasal swabs, or how participants 168 169 were selected. Even if we assume all persons in those studies were symptomatic, the 73% 170 sensitivity we found among persons with symptoms was still much lower in the product insert. It 171 is possible that individuals in the manufacturer's study had more severe COVID-19 disease 172 compared to our participants, with a higher viral load and thereby more likely to be detected by 173 an antigen test [13,14].

Several published studies have also evaluated the performance of LumiraDx compared to PCR as the gold standard. Similar to our findings, most found a high specificity among both symptomatic and asymptomac individuals [15-18]. Reported sensitivity varied widely, however. Some studies found sensitivities of 90% or greater [15,17,18], while others reported values closer to the 73% we observed [19,16,20]. It is worth noting that studies reporting a high sensitivity primarily tested patients in emergency departments or residents of nursing homes, who might have been sicker than our participants [15,18,17]. Studies that found a lower sensitivity generally

evaluated individuals seeking care at outpatient departments, who may have been more similarour ambulatory sample [19,21].

183 The variability in test performance among studies and by patient population, highlights 184 the importance of evaluating test diagnostics in the population and setting in which they are to be used. In addition, the probability that a negative or a positive test finding is accurate depends on 185 186 the probability of true infection among persons being tested, which varies across geographic 187 regions, and is another reason to determine the accuracy of a test where it will be used. It should 188 be noted that the only other study from SSA that evaluated LumiraDx in addition to ours was 189 performed in Mozambique, and found similarly low sensitivity as in our study, or 80% among 190 those with symptoms, and 48% among those who were asymptomatic[21].

We do not believe that the low sensitivity we found was due to laboratory or other 191 procedural errors. The on-site research laboratory used for many other PREVAIL studies in 192 addition to PCOS, conducts verification and validation testing to ensure the accuracy and 193 194 reliability of findings. However, our study did have several limitations. First, the sample size for asymptomatic individuals was small, resulting in wide confidence intervals around some 195 estimates. Secondly, the manufacturer recommends that LumiraDx not be used more than 12 196 197 days after symptom onset. We did not collect information about when symptoms began; therefore, it is possible that the low sensitivity and NPV among symptomatic participants could 198 partially be a results of including persons beyond the window of detection for the LumiraDx. 199 200 Finally, we only asked participants about 10 possible COVID-19 related symptoms. Since then, 201 many additional symptoms have been associated with acute SARS-CoV-2 infection [24]. 202 Misclassifying some persons with COVID-19 symptoms that we did not recognize, could have resulted in us calculating a somewhat falsely low NPV. 203

204 The LumiraDx platform could be a useful test to quickly triage persons with a positive 205 antigen test in clinical and resource limited settings when confirmatory NAAT testing is not rapidly available or affordable [22-24]. The turnaround time to obtain a test result once the 206 207 sample has been inserted into the machine, is only 12 minutes, and use of the platform does not required skilled technicians. The main logistical drawbacks are that the platorm needs to be used 208 209 in a laboratory setting, and only one sample can be evaluated at a time. Despite the several 210 advantages of the LumiraDx diagnostic test, however, the low NPV means that a negative result 211 in someome with symptoms can not be used to rule-out an infection, requiring a confirmatory 212 test.

213 Our study demonstrated both the potential usefulness and limitations of using this antigen 214 test in a country in west Africa, and highlighted the importance of not assuming published test 215 performance is applicable across regions and different populations. The COVID-19 pandemic 216 has waned, and the urgency of alternative screening and testing methods for SARS-CoV-2 217 infection is no longer acute. During the last several years, home-based and self-administered 218 testing using convenient and rapid lateral flow tests have been widely used in many parts of the 219 world. Unfortunately, they have never become available in Liberia. Nevertheless, transmission 220 of infections has steadily declined in Liberia similar to other countries[6], likely due to a combination of immunity from infection and vaccination, and circulation of less virulent 221 222 variants. Despite the present reduced threat from this infection, the initial severe and highly 223 distruptive impact of the SARS-CoV-2 pandemic warns us of the potential spread and 224 consequences of a pathogen against which the global community is unprepared, and the need to 225 assess novel diagnostic tools, particularly for new pathogens, in the population in which they will

- be used. The scientific and public health community should not assume validated tests will
- 227 perform similarly in different populations.

228

## 230 Acknowledgements

- 231 We thank staff at the Ministry of Health, Liberia and JKF Medical Center for their
- collaboration in making this study possible. We would also like to acknowledge the contribution
- of the PCOS study team for implementing the study, and the laboratory staff for conducting the
- testing. We also gratefully acknowledge all the participants.

## 236 Authors' Declarations

- All named authors have seen and agreed to the submitted version of the paper. The material
- is original and is unpublished in another journal; it not currently being submitted elsewhere for
- 239 publication. Preliminary information from the study was presented as an absract at the
- 240 International Conference of the West African Consortium.

## 241 **Declaration of Competing Interest**

- 242 The authors declare no conflicts of interest.
- 243
- 244

## 245 Author Contributions

246	Moses Badio: Conceptualization, Data curation, Formal analysis, Investigation, Methodology,
247	Project administration, Supervision, Visualization, Writing – original draft, Writing – review &
248	editing. Christina Lindan: Funding acquisition for analysis and writing, Methodology of
249	analysis, Supervision, Visualization, Writing – original draft, Writing – review & editing.
250	Kumblytee Johnson: Conceptualization, Data curation, Investigation, Methodology, Project
251	administration, Resources, Supervision, Writing – review & editing. Cavan Reilly:
252	Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization,
253	Writing – review & editing. Julie Blie: Validation, Data curation, Project administration,
254	Supervision. Katy Saliba: Validation, Project administration, Resources, Supervision, Writing –
255	review & editing. Tamba Fayiah: Data curation, Writing – review & editing. John
256	McCullough: Validation, Data curation, Project administration, Supervision. James Duworko:
257	Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing.
258	Elizabeth Higgs: Conceptualization, Funding acquisition, Investigation, Methodology,
259	Resources, Supervision, Writing – review & editing. Jeff Martin: Funding acquisition,
260	Methodology, Resources, Supervision, Visualization, Writing – original draft, Writing – review
261	& editing. Lisa Hensley: Conceptualization, Funding acquisition, Investigation, Methodology,
262	Resources, Supervision, Visualization, Writing – review & editing.

#### 263 Table 1. Demographic characteristics and symptoms of participants tested for SARS-CoV-2 infection

with LumiraDx<sup>™</sup> antigen test and BioFire<sup>®</sup> PCR, Monrovia, Liberia, June – August 2021

	Ν	%
All	348	100
Age <sup>1</sup> , years		
≤30	152	44.3%
31-50	63	18.4%
>50	128	37.3%
Female	154	44.3%
Symptomatic		
Any symptom	274	78.7%
Symptoms <sup>2</sup>		
Fever	129	37.1%
Cough	147	42.2%
Sneezing	56	16.1%
Sore throat	40	11.5%
Shortness of breath	121	34.8%
Absence of smell	66	19.0%
Weakness/fatigu e	177	50.9%
Body pain	132	37.9%
Headache	123	35.3%
Diarrhea	33	9.5%


265

<sup>1</sup>Small differences in N are due to missing data

<sup>2</sup>Only among the 274 who had at least one symptom

# Table 2. LumiraDx<sup>™</sup> SARS-CoV-2 antigen test performance compared to BioFire<sup>®</sup> R2.1P PCR among persons with and without COVID-19 symptoms, Monrovia, Liberia, June – August 2021

	BioFire						
	LumiraDx	Positive	Negative	All	LumiraDx test performance	%	(95% CI)
	All				Sensitivity	70.8%	[62.7%, 78.1%]
	Positive	102	2	104	Specificity	99.0%	[96.5%, 99.9%]
	Negative	42	202	244	Positive predictive value	98.1%	[93.2%, 99.8%]
	Total	144	204	348	Negative predictive value	82.8%	[77.5%, 87.3%]
	Symptoma				Sensitivity	72.6%	[64.3%, 79.9%]
	Positive	98	2	100	Specificity	98.6%	[94.9%, 99.8%]
	Negative	37	137	174	Positive predictive value	98.0%	[93.0%, 99.8%]
	Total	135	139	274	Negative predictive value	78.7%	[71.9%, 84.6%]
	Asymptom				Sensitivity	44.4%	[13.7%, 78.8%]
	Positive	4	0	4	Specificity	100.0%	[94.5%, 100%]
	Negative	5	65	70	Positive predictive value	100.0%	[39.8%, 100%]
69	Total	9	65	74	Negative predictive value	92.9%	[84.1%, 97.6%]
70							
71							
72							
72 73							
73							
73 74							
73 74 75							
73 74 75 76							
73 74 75 76 77							
73 74 75 76 77 78							
73 74 75 76 77 78 79							
73 74 75 76 77 78 79 80							



284

## **Figure 1. Predictive value of the LumiraDx™antigen test in populations with varying prevalence of**

acute SARS-CoV-2 infection, among symptomatic and asymptomatic individuals.

#### 287 Note: The specificity among asymptomatic individuals is 100%. Hence, the PPV cannot be calculated.

#### 288 **References**

A. Babiker, C. W. Myers, C. E. Hill, and J. Guarner, "SARS-CoV-2 TestingTrials and 289 [1] 290 Tribulations," Am. J. Clin. Pathol., vol. 153, no. 6, pp. 706–708, May 2020, doi: 10.1093/AJCP/AQAA052. 291 292 [2] N. R. Blumenfeld *et al.*, "Multiplexed reverse-transcriptase quantitative polymerase chain reaction using plasmonic nanoparticles for point-of-care COVID-19 diagnosis," Nat. 293 294 Nanotechnol., Jul. 2022, doi: 10.1038/S41565-022-01175-4. 295 [3] D. B. Larremore et al., "Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance," medRxiv Prepr. Serv. Heal. Sci., Sep. 2020, doi: 296 10.1101/2020.06.22.20136309. 297 K. S. Liu, X. D. Mao, W. Ni, and T. P. Li, "Laboratory detection of SARS-CoV-2: A 298 [4] review of the current literature and future perspectives," Heliyon, vol. 8, no. 10, p. e10858, 299 Oct. 2022, doi: 10.1016/J.HELIYON.2022.E10858. 300 B. Shobayo et al., "SARS-CoV-2 Sequence Analysis during COVID-19 Case Surge, 301 [5] Liberia, 2021," Emerg. Infect. Dis., vol. 27, no. 12, pp. 3185–3188, Dec. 2021, doi: 302 10.3201/EID2712.211818. 303 304 [6] "Liberia: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data WHO Coronavirus (COVID-19) Dashboard With Vaccination Data." 305 306 https://covid19.who.int/region/afro/country/lr (accessed June. 7, 2023). O. O. Oleribe, A. A. A. Suliman, S. D. Taylor-Robinson, and T. Corrah, "Possible 307 [7] 308 Reasons Why Sub-Saharan Africa Experienced a Less Severe COVID-19 Pandemic in 2020," J. Multidiscip. Healthc., vol. 14, pp. 3267–3271, Dec. 2021, doi: 309 10.2147/JMDH.S331847. 310 [8] A. Kalungi, E. Kinyanda, D. H. Akena, P. Kaleebu, and I. M. Bisangwa, "Less Severe 311 Cases of COVID-19 in Sub-Saharan Africa: Could Co-infection or a Recent History of 312 313 Plasmodium falciparum Infection Be Protective?," Front. Immunol., vol. 12, p. 565625, 314 2021, doi: 10.3389/fimmu.2021.565625. FDA, "BioFire COVID-19 Test - Letter of Authorization," 2023. 315 [9]

- 316 [10] FDA, "LumiraDx SARS-CoV-2 RNA STAR Complete Letter of Authorization," 2023,
- https://www.fda.gov/media/152406/download, (accessed June 07, 2023).
- 318 [11] "Respiratory Pathogen Panel Test | BioFire Diagnostics."
- https://www.biofiredx.com/products/the-filmarray-panels/filmarrayrp/ (accessed June 07,
  2023).
- [12] "COVID-19 SARS-CoV-2 Antigen Test | LumiraDx." https://www.lumiradx.com/us en/test-menu/antigen-test (accessed June 07, 2023).
- 323 [13] "LumiraDx SARS-CoV-2 Ag Test," Feb. 2022.
- 324 https://www.lumiradx.com/assets/pdfs/covid-19-antigen-test/sars-cov-2-antigen-product-
- insert/sars-cov-2-ag-test-strip-product-insert-eua.pdf?v=8, (accessed: June 07, 2023).
- [14] P. K. Drain *et al.*, "A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay
  to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance
  Study," *Infect. Dis. Ther.*, vol. 10, no. 2, 2021, doi: 10.1007/s40121-021-00413-x.
- J. Fajnzylber *et al.*, "SARS-CoV-2 viral load is associated with increased disease severity
  and mortality," *Nat. Commun.*, vol. 11, no. 1, p. 5493, 2020, doi: 10.1038/s41467-02019057-5.
- F. Yu *et al.*, "Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected
  Patients," *Clin. Infect. Dis.*, vol. 71, no. 15, pp. 793–798, Jul. 2020, doi:
  10.1093/cid/ciaa345.
- 335 [17] M. Domínguez Fernández, A. Seoane Estévez, F. Lamelo Alfonsín, and G. Bou,
- <sup>336</sup> "Usefulness of the Lumiradx<sup>™</sup> SARS-COV-2 antigen test in nursing home.,"
- 337 *Enfermedades infecciosas y microbiologia clinica (English ed.)*, vol. 40, no. 7. Spain, pp.
- 404–405, 2022. doi: 10.1016/j.eimce.2022.04.008.
- L. J. Krüger *et al.*, "Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use
   of LumiraDx<sup>TM</sup>: An antigen-detecting point-of-care device for SARS-CoV-2," *Infection*,
   2021, doi: 10.1007/s15010-021-01681-y.
- E. Burdino *et al.*, "SARS-CoV-2 microfluidic antigen point-of-care testing in Emergency
  Room patients during COVID-19 pandemic.," *J. Virol. Methods*, vol. 299, p. 114337, Jan.

2022, doi: 10.1016/j.jviromet.2021.114337.

J. E. Ellis, P. Guest, V. Lawson, J. Loecherbach, N. Lindner, and A. McCulloch, 345 [20] 346 "Performance Evaluation of the Microfluidic Antigen LumiraDx SARS-CoV-2 and Flu A/B Test in Diagnosing COVID-19 and Influenza in Patients with Respiratory 347 Symptoms.," Infect. Dis. Ther., vol. 11, no. 6, pp. 2099–2109, Dec. 2022, doi: 348 10.1007/s40121-022-00696-8. 349 N. Sitoe et al., "Clinical Performance of Self-Collected Nasal Swabs and Antigen Rapid 350 [21] Tests for SARS-CoV-2 Detection in Resource-Poor Settings.," Biomedicines, vol. 10, no. 351 9, Sep. 2022, doi: 10.3390/biomedicines10092327. 352 353 [22] M. Micocci et al., "Point of care testing using rapid automated antigen testing for SARS-COV-2 in care homes – an exploratory safety, usability and diagnostic agreement 354 355 evaluation," J. Patient Saf. Risk Manag., vol. 26, no. 6, 2021, doi: 356 10.1177/25160435211054207. L. J. Krüger *et al.*, "Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use 357 [23] of LumiraDx<sup>TM</sup>: An antigen-detecting point-of-care device for SARS-CoV-2.," Infection, 358 vol. 50, no. 2, pp. 395–406, Apr. 2022, doi: 10.1007/s15010-021-01681-y. 359 360 [24] C. Chakraborty, A. R. Sharma, G. Sharma, M. Bhattacharya, and S. S. Lee, "SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and 361 362 proposed therapeutic options.," Eur. Rev. Med. Pharmacol. Sci., vol. 24, no. 7, pp. 4016-4026, Apr. 2020, doi: 10.26355/eurrev 202004 20871. 363 Z. Duma, V. Ramsuran, A. A. Chuturgoon, V. A. Edward, P. Naidoo, and Z. L. Mkhize-364 [25] Kwitshana, "Evaluation of Various Alternative Economical and High Throughput SARS-365 CoV-2 Testing Methods within Resource-Limited Settings," International Journal of 366 Molecular Sciences, vol. 23, no. 22. 2022. doi: 10.3390/ijms232214350. 367 368 [26] Z. Duma *et al.*, "The challenges of severe acute respiratory syndrome coronavirus 2 369 (SARS-CoV-2) testing in low-middle income countries and possible cost-effective measures in resource-limited settings," Global. Health, vol. 18, no. 1, p. 5, 2022, doi: 370 371 10.1186/s12992-022-00796-7.